PB1938: 4WHIM: EVALUATING MAVORIXAFOR, AN ORAL CXCR4 ANTAGONIST, IN PATIENTS WITH WHIM SYNDROME VIA A GLOBAL PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED TRIAL WITH OPEN-LABEL EXTENSION

ABSTRACT:

SUBMITTER: Dale D 

PROVIDER: S-EPMC9431515 | biostudies-literature | 2022 Jun

REPOSITORIES: biostudies-literature